397 related articles for article (PubMed ID: 19673466)
1. Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
Wan ZK; Chenail E; Xiang J; Li HQ; Ipek M; Bard J; Svenson K; Mansour TS; Xu X; Tian X; Suri V; Hahm S; Xing Y; Johnson CE; Li X; Qadri A; Panza D; Perreault M; Tobin JF; Saiah E
J Med Chem; 2009 Sep; 52(17):5449-61. PubMed ID: 19673466
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
4. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
6. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
7. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
8. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
[TBL] [Abstract][Full Text] [Related]
11. 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
Jean DJ; Yuan C; Bercot EA; Cupples R; Chen M; Fretland J; Hale C; Hungate RW; Komorowski R; Veniant M; Wang M; Zhang X; Fotsch C
J Med Chem; 2007 Feb; 50(3):429-32. PubMed ID: 17266194
[TBL] [Abstract][Full Text] [Related]
12. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
[TBL] [Abstract][Full Text] [Related]
13. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
14. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
[TBL] [Abstract][Full Text] [Related]
15. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
16. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
[TBL] [Abstract][Full Text] [Related]
17. The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.
Yuan C; St Jean DJ; Liu Q; Cai L; Li A; Han N; Moniz G; Askew B; Hungate RW; Johansson L; Tedenborg L; Pyring D; Williams M; Hale C; Chen M; Cupples R; Zhang J; Jordan S; Bartberger MD; Sun Y; Emery M; Wang M; Fotsch C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6056-61. PubMed ID: 17919905
[TBL] [Abstract][Full Text] [Related]
18. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
19. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
20. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
